Monocyte heterogeneity and functions in cancer

Abstract

Monocytes are innate immune cells of the mononuclear phagocyte system that have emerged as important regulators of cancer development and progression. Our understanding of monocytes has advanced from viewing these cells as a homogenous population to a heterogeneous system of cells that display diverse responses to different stimuli. During cancer, different monocyte subsets perform functions that contribute to both pro- and antitumoral immunity, including phagocytosis, secretion of tumoricidal mediators, promotion of angiogenesis, remodeling of the extracellular matrix, recruitment of lymphocytes, and differentiation into tumor-associated macrophages and dendritic cells. The ability of cancer to evade immune recognition and clearance requires protumoral signals to outweigh ongoing attempts by the host immune system to prevent tumor growth. This review discusses current understanding of monocyte heterogeneity during homeostasis, highlights monocyte functions in cancer progression, and describes monocyte-targeted therapeutic strategies for cancer treatment.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 146

1. 1.

   Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762–774.

   Not in our library10.1038/nri3070

2. 2.

   Qian B‐Z, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast‐tumour metastasis. Nature. 2011;475:222–225.

   Not in our library10.1038/nature10138

3. 3.

   Hanna RN, Cekic C, Sag D, et al. Patrolling monocytes control tumor metastasis to the lung. Science. 2015;350:985–990.

   Not in our library10.1126/science.aac9407

4. 4.

   Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16:447–462.

   Not in our library10.1038/nrc.2016.54

5. 5.

   Ziegler‐Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:e74–e80.

   Not in our library10.1182/blood-2010-02-258558

6. 6.

   Passlick B, Flieger D, Ziegler‐Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74:2527–2534.

   Not in our library

7. 7.

   Palframan RT, Jung S, Cheng G, et al. Inflammatory chemokine transport and presentation in hev: A remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med. 2001;194:1361–1374.

   Not in our library10.1084/jem.194.9.1361

8. 8.

   Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71–82.

   Not in our library10.1016/s1074-7613(03)00174-2

9. 9.

   Sunderkötter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol. 2004;172:4410–4417.

   Not in our library10.4049/jimmunol.172.7.4410

10. 10.

    Ingersoll MA, Spanbroek R, Lottaz C, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010;115:e10–e19.

    Not in our library10.1182/blood-2009-07-235028

11. 11.

    Mildner A, Schönheit J, Giladi A, et al. Genomic characterization of murine monocytes reveals C/EBPβ transcription factor dependence of Ly6C− cells. Immunity. 2017;46:849–862.

    Not in our library10.1016/j.immuni.2017.04.018

12. 12.

    Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33:375–386.

    Not in our library10.1016/j.immuni.2010.08.012

13. 13.

    Thomas GD, Hamers AAJ, Nakao C, et al. Human blood monocyte subsets: a new gating strategy defined using cell surface markers identified by mass cytometry. Arterioscler Thromb Vasc Biol. 2017;37:1548–1558.

    Not in our library10.1161/atvbaha.117.309145

14. 14.

    Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen‐presenting functions. Nat Rev Immunol. 2017;2018:349–362.

    Not in our library10.1038/nri.2017.28

15. 15.

    Briseño CG, Haldar M, Kretzer NM, et al. Distinct transcriptional programs control cross‐priming in classical and monocyte‐derived dendritic cells. Cell Rep. 2016;15:2462–2474.

    Not in our library10.1016/j.celrep.2016.05.025

16. 16.

    Villani A‐C, Satija R, Reynolds G, et al. Single‐cell RNA‐seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356:eaah4573.

    Not in our library10.1126/science.aah4573

17. 17.
    The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells · 2016

    No notice
18. 18.

    Hettinger J, Richards DM, Hansson J, et al. Origin of monocytes and macrophages in a committed progenitor. Nat Immunol. 2013;14:821–830.

    Not in our library10.1038/ni.2638

19. 19.

    Kawamura S, Onai N, Miya F, et al. Identification of a human clonogenic progenitor with strict monocyte differentiation potential: a counterpart of mouse cMoPs. Immunity. 2017;46:835–848.

    Not in our library10.1016/j.immuni.2017.04.019

20. 20.

    Zhu YP, Thomas GD, Hedrick CC. 2014 Jeffrey M. Hoeg award lecture: transcriptional control of monocyte development. Arterioscler Thromb Vasc Biol. 2016;36:1722–1733.

    Not in our library10.1161/atvbaha.116.304054

21. 21.

    Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265:1573–1577.

    Not in our library10.1126/science.8079170

22. 22.

    Kurotaki D, Yamamoto M, Nishiyama A, et al. IRF8 inhibits C/EBPα activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. Nat Commun. 2014;5:4978.

    Not in our library10.1038/ncomms5978

23. 23.

    Kurotaki D, Osato N, Nishiyama A, et al. Essential role of the IRF8‐KLF4 transcription factor cascade in murine monocyte differentiation. Blood. 2013;121:1839–1849.

    Not in our library10.1182/blood-2012-06-437863

24. 24.

    Lee J, Breton G, Oliveira TYK, et al. Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. J Exp Med. 2015;212:385–399.

    Not in our library10.1084/jem.20141442

25. 25.

    Yáñez A, Coetzee SG, Olsson A, et al. Granulocyte‐Monocyte progenitors and monocyte‐dendritic cell progenitors independently produce functionally distinct monocytes. Immunity. 2017;47:890–902.

    Not in our library10.1016/j.immuni.2017.10.021

26. 26.

    Yona S, Kim K‐W, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91.

    Not in our library10.1016/j.immuni.2012.12.001

27. 27.

    Varol C, Landsman L, Fogg DK, et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med. 2007;204:171–180.

    Not in our library10.1084/jem.20061011

28. 28.
    The fate and lifespan of human monocyte subsets in steady state and systemic inflammation · 2017

    No notice
29. 29.

    Hanna RN, Carlin LM, Hubbeling HG, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C− monocytes. Nat Immunol. 2011;12:778–785.

    Not in our library10.1038/ni.2063

30. 30.

    Thomas GD, Hanna RN, Vasudevan NT, et al. Deleting an Nr4a1 super‐enhancer subdomain ablates Ly6Clow monocytes while preserving macrophage gene function. Immunity. 2016;45:975–987.

    Not in our library10.1016/j.immuni.2016.10.011

31. 31.

    Tamura A, Hirai H, Yokota A, et al. C/EBPβ is required for survival of Ly6C− monocytes. Blood. 2017;130:1809–1818.

    Not in our library10.1182/blood-2017-03-772962

32. 32.
    Regulation of monocyte cell fate by blood vessels mediated by Notch signalling · 2016

    Corrected
33. 33.

    Satoh T, Nakagawa K, Sugihara F, et al. Identification of an atypical monocyte and committed progenitor involved in fibrosis. Nature. 2017;541:96–101.

    Not in our library10.1038/nature20611

34. 34.

    Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006;7:311–317.

    Not in our library10.1038/ni1309

35. 35.

    Jakubzick C, Gautier EL, Gibbings SL, et al. Minimal differentiation of classical monocytes as they survey steady‐state tissues and transport antigen to lymph nodes. Immunity. 2013;39:599–610.

    Not in our library10.1016/j.immuni.2013.08.007

36. 36.

    Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317:666–670.

    Not in our library10.1126/science.1142883

37. 37.

    Debien E, Mayol K, Biajoux V, et al. S1PR5 is pivotal for the homeostasis of patrolling monocytes. Eur J Immunol. 2013;43:1667–1675.

    Not in our library10.1002/eji.201343312

38. 38.

    Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single‐cell analyses. Cell. 2017;169:750–765.

    Not in our library10.1016/j.cell.2017.04.014

39. 39.

    Azizi E, Carr AJ, Plitas G, et al. Single‐Cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174:1293–1308.

    Not in our library10.1016/j.cell.2018.05.060

40. 40.

    Jakubzick C, Tacke F, Ginhoux F, et al. Blood monocyte subsets differentially give rise to CD103+ and CD103− pulmonary dendritic cell populations. J Immunol. 2008;180:3019–3027.

    Not in our library10.4049/jimmunol.180.5.3019

41. 41.

    Guilliams M, Ginhoux F, Jakubzick C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14:571–578.

    Not in our library10.1038/nri3712

42. 42.

    Guilliams M, Scott CL. Does niche competition determine the origin of tissue‐resident macrophages?. Nat Rev Immunol. 2017;17:451–460.

    Not in our library10.1038/nri.2017.42

43. 43.

    van de Laar L, Saelens W, De Prijck S, et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue‐resident macrophages. Immunity. 2016;44:755–768.

    Not in our library10.1016/j.immuni.2016.02.017

44. 44.

    Goudot C, Coillard A, Villani A‐C, et al. Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages. Immunity. 2017;47:582–596.

    Not in our library10.1016/j.immuni.2017.08.016

45. 45.
    Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal · 2013

    No notice
46. 46.

    Misharin AV, Cuda CM, Saber R, et al. Nonclassical Ly6C− monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 2014;9:591–604.

    Not in our library10.1016/j.celrep.2014.09.032

47. 47.
    Non-classical monocytes are biased progenitors of wound healing macrophages during soft tissue injury · 2017

    No notice
48. 48.

    Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor‐associated macrophages. Science. 2014;344:921–925.

    Not in our library10.1126/science.1252510

49. 49.

    Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte‐to‐macrophage differentiation and polarization: New molecules and patterns of gene expression. J Immunol. 2006;177:7303–7311.

    Not in our library10.4049/jimmunol.177.10.7303

50. 50.

    Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity. Oct. 2018;49:595–613.

    Not in our library10.1016/j.immuni.2018.10.005

51. 51.

    Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728–5739.

    Not in our library10.1158/0008-5472.can-09-4672

52. 52.
    Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer · 2018

    No notice
53. 53.

    Chun E, Lavoie S, Michaud M, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid‐derived suppressor cell population and function. Cell Rep. 2015;12:244–257.

    Not in our library10.1016/j.celrep.2015.06.024

54. 54.

    Cortez‐Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor‐associated macrophages and neutrophils. Proc Natl Acad Sci USA. 2012;109:2491–2496.

    Not in our library10.1073/pnas.1113744109

55. 55.

    Wu C, Ning H, Liu M, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor‐promoting myelopoiesis. J Clin Invest. 2018;128:3425–3438.

    Not in our library10.1172/jci97973

56. 56.

    Shand FHW, Ueha S, Otsuji M, et al. Tracking of intertissue migration reveals the origins of tumor‐infiltrating monocytes. Proc Natl Acad Sci USA. May 2014;111:7771–7776.

    Not in our library10.1073/pnas.1402914111

57. 57.

    Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte‐mediated tumoricidal activity via the tumor necrosis factor–related cytokine, TRAIL. J Exp Med. 1999;189:1343–1354.

    Not in our library10.1084/jem.189.8.1343

58. 58.
    The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 · 2017

    No notice
59. 59.

    Gordon IO, Freedman RS. Defective antitumor function of monocyte‐derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12:1515–1524.

    Not in our library10.1158/1078-0432.ccr-05-2254

60. 60.
    CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes · 2016

    Corrected
61. 61.

    Chittezhath M, Dhillon MK, Lim JY, et al. Molecular profiling reveals a tumor‐promoting phenotype of monocytes and macrophages in human cancer progression. Immunity. 2014;41:815–829.

    Not in our library10.1016/j.immuni.2014.09.014

62. 62.

    Lee Y, Chittezhath M, André V, et al. Protumoral role of monocytes in human B‐cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood. 2012;119:227–237.

    Not in our library10.1182/blood-2011-06-357442

63. 63.

    Hamm A, Prenen H, Van Delm W, et al. Tumour‐educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow‐up of colorectal cancer. Gut. 2016;65:990–1000.

    Not in our library10.1136/gutjnl-2014-308988

64. 64.

    Headley MB, Bins A, Nip A, et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature. 2016;531:513–517.

    Not in our library10.1038/nature16985

65. 65.

    Jaiswal S, Jamieson CHM, Pang WW, et al. CD47 is up‐regulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–285.

    Not in our library10.1016/j.cell.2009.05.046

66. 66.

    Chao MP, Alizadeh AA, Tang C, et al. Anti‐CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non‐hodgkin lymphoma. Cell. 2010;142:699–713.

    Not in our library10.1016/j.cell.2010.07.044

67. 67.

    Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47‐signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109:6662–6667.

    Not in our library10.1073/pnas.1121623109

68. 68.
    CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer · 2016

    No notice
69. 69.

    Kubo H, Mensurado S, Gonçalves‐Sousa N, Serre K, Silva‐Santos B. Primary tumors limit metastasis formation through induction of IL15‐Mediated cross‐talk between patrolling monocytes and NK cells. Cancer Immunol Res. 2017;5:812–820.

    Not in our library10.1158/2326-6066.cir-17-0082

70. 70.
    Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche · 2017

    No notice
71. 71.

    Veglia F, Perego M, Gabrilovich D. Myeloid‐derived suppressor cells coming of age. Nat Immunol. 2018;19:108–119.

    Not in our library10.1038/s41590-017-0022-x

72. 72.

    Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor‐infiltrating macrophages decreases tumor‐Initiating cells, relieves immunosuppression and improves chemotherapeutic response. Cancer Res. 2012;73:2012–1141.

    Not in our library10.1158/0008-5472.can-12-2731

73. 73.

    Li X, Yao W, Yuan Y, et al. Targeting of tumour‐infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157–167.

    Not in our library10.1136/gutjnl-2015-310514

74. 74.

    Lesokhin AM, Hohl TM, Kitano S, et al. Monocytic CCR2(+) myeloid‐derived suppressor cells promote immune escape by limiting activated CD8 T‐cell infiltration into the tumor microenvironment. Cancer Res. 2012;72:876–886.

    Not in our library10.1158/0008-5472.can-11-1792

75. 75.

    Sawanobori Y, Ueha S, Kurachi M, et al. Chemokine‐mediated rapid turnover of myeloid‐derived suppressor cells in tumor‐bearing mice. Blood. 2008;111:5457–5466.

    Not in our library10.1182/blood-2008-01-136895

76. 76.

    Sanford DE, Belt BA, Panni RZ, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013;19:3404–3415.

    Not in our library10.1158/1078-0432.ccr-13-0525

77. 77.

    Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4:345–353.

    Not in our library10.1158/2326-6066.cir-15-0193

78. 78.

    Schlecker E, Stojanovic A, Eisen C, et al. Tumor‐Infiltrating monocytic myeloid‐derived suppressor cells mediate CCR5‐Dependent recruitment of regulatory T Cells favoring tumor growth. J Immunol. 2012;189:5602–5611.

    Not in our library10.4049/jimmunol.1201018

79. 79.

    Pommier A, Audemard A, Durand A, et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. Proc Natl Acad Sci USA. 2013;110:13085–13090.

    Not in our library10.1073/pnas.1300314110

80. 80.

    Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJC, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA. 2007;104:19446–19451.

    Not in our library10.1073/pnas.0706832104

81. 81.

    Romano E, Kusio‐Kobialka M, Foukas PG, et al. Ipilimumab‐dependent cell‐mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015;112:6140–6145.

    Not in our library10.1073/pnas.1417320112

82. 82.

    Kuhn S, Yang J, Ronchese F. Monocyte‐Derived dendritic cells are essential for CD8+ T cell activation and antitumor responses after local immunotherapy. Frontiers in Immunology. 2015;6:e17515.

    Not in our library10.3389/fimmu.2015.00584

83. 83.

    Sheng J, Chen Q, Soncin I, Ng SL, Karjalainen K, Ruedl C. A discrete subset of monocyte‐derived cells among typical conventional type 2 dendritic cells can efficiently cross‐present. Cell Rep. 2017;21:1203–1214.

    Not in our library10.1016/j.celrep.2017.10.024

84. 84.
    Effector CD4+ T cells recognize intravascular antigen presented by patrolling monocytes · 2018

    Not checked
85. 85.

    Rivera LB, Bergers G. Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol. 2015;36:240–249.

    Not in our library10.1016/j.it.2015.02.005

86. 86.

    Du R, Lu KV, Petritsch C, et al. HIF1α induces the recruitment of bone marrow‐derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13:206–220.

    Not in our library10.1016/j.ccr.2008.01.034

87. 87.

    Sidibe A, Ropraz P, Jemelin S, et al. Angiogenic factor‐driven inflammation promotes extravasation of human proangiogenic monocytes to tumours. Nat Commun. 2018;9:355.

    Not in our library10.1038/s41467-017-02610-0

88. 88.

    Zhang W, Zhu X‐D, Sun H‐C, et al. Depletion of tumor‐associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010;16:3420–3430.

    Not in our library10.1158/1078-0432.ccr-09-2904

89. 89.

    Gazzaniga S, Bravo AI, Guglielmotti A, et al. Targeting tumor‐associated macrophages and inhibition of MCP‐1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol. 2007;127:2031–2041.

    Not in our library10.1038/sj.jid.5700827

90. 90.
    A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation · 2018

    No notice
91. 91.

    De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8:211–226.

    Not in our library10.1016/j.ccr.2005.08.002

92. 92.

    Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2‐expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;109:5276–5285.

    Not in our library10.1182/blood-2006-10-053504

93. 93.

    Coffelt SB, Tal AO, Scholz A, et al. Angiopoietin‐2 regulates gene expression in TIE2‐Expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010;70:5270–5280.

    Not in our library10.1158/0008-5472.can-10-0012

94. 94.

    Harney AS, Arwert EN, Entenberg D, et al. Real‐Time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage–derived VEGFA. Cancer Discov. 2015;5:932–943.

    Not in our library10.1158/2159-8290.cd-15-0012

95. 95.

    Coffelt SB, Chen Y‐Y, Muthana M, et al. Angiopoietin 2 stimulates TIE2‐Expressing monocytes to suppress T Cell activation and to promote regulatory T cell expansion. J Immunol. 2011;186:4183–4190.

    Not in our library10.4049/jimmunol.1002802

96. 96.

    Bergers G, Hanahan D. Modes of resistance to anti‐angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.

    Not in our library10.1038/nrc2442

97. 97.

    Jung K, Heishi T, Khan OF, et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti‐VEGFR2 cancer therapy. J Clin Invest. 2017;127:3039–3051.

    Not in our library10.1172/jci93182

98. 98.

    Xu L, Duda DG, di Tomaso E, et al. Direct evidence that bevacizumab, an anti‐VEGF antibody, up‐regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009;69:7905–7910.

    Not in our library10.1158/0008-5472.can-09-2099

99. 99.

    Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti‐VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25:911–920.

    Not in our library10.1038/nbt1323

100. 100.
     Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach · 2006

     No notice
101. 101.

     Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196:395–406.

     Not in our library10.1083/jcb.201102147

102. 102.

     Porrello A, Leslie PL, Harrison EB, et al. Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross‐linking. Nat Commun. 2018;9:1988.

     Not in our library10.1038/s41467-018-04355-w

103. 103.

     Madsen DH, Jürgensen HJ, Siersbæk MS, et al. Tumor‐associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake. Cell Rep. 2017;21:3662–3671.

     Not in our library10.1016/j.celrep.2017.12.011

104. 104.

     Loyher P‐L, Hamon P, Laviron M, et al. Macrophages of distinct origins contribute to tumor development in the lung. J Exp Med. 2018;87:jem.20180534.

     Not in our library10.1084/jem.20180534

105. 105.

     Lu H, Clauser KR, Tam WL, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16:1105–1117.

     Not in our library10.1038/ncb3041

106. 106.

     Lapenna A, De Palma M, Lewis CE. Perivascular macrophages in health and disease. Nat Rev Immunol. 2018;2018:689–702.

     Not in our library10.1038/s41577-018-0056-9

107. 107.

     Forssell J, Öberg, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13:1472–1479.

     Not in our library10.1158/1078-0432.ccr-06-2073

108. 108.

     Noy R, Pollard JW. Tumor‐Associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61.

     Not in our library10.1016/j.immuni.2014.06.010

109. 109.

     Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour‐associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416.

     Not in our library10.1038/nrclinonc.2016.217

110. 110.

     Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen‐presenting cells critical for T cell immunity. Cancer Cell. 2014;26:638–652.

     Not in our library10.1016/j.ccell.2014.09.007

111. 111.

     Sharma MD, Rodriguez PC, Koehn BH, Baban B, Immunity YC. Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c+CD103+ monocytic antigen‐presenting cells in tumors. Immunity. 2018;48:91–106.

     Not in our library10.1016/j.immuni.2017.12.014

112. 112.

     Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high‐risk patients in diffuse large‐B‐cell lymphoma. Leukemia. 2011;25:1502–1509.

     Not in our library10.1038/leu.2011.112

113. 113.

     Lee Y‐Y, Choi CH, Sung CO, et al. Prognostic value of pre‐treatment circulating monocyte count in patients with cervical cancer: comparison with SCC‐Ag level. Gynecol Oncol. 2012;124:92–97.

     Not in our library10.1016/j.ygyno.2011.09.034

114. 114.
     Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP · 2012

     No notice
115. 115.

     Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–440.

     Not in our library10.1038/bjc.2013.785

116. 116.
     Prognostic Significance of Systemic Inflammation-Based Lymphocyte- Monocyte Ratio in Patients with Lung Cancer: Based on a Large Cohort Study · 2014

     No notice
117. 117.

     Eo WK, Chang HJ, Kwon SH, et al. The lymphocyte‐monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer. 2016;7:289–296.

     Not in our library10.7150/jca.13432

118. 118.

     Lu Y, Cai Z, Xiao G, et al. CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 2007;101:676–685.

     Not in our library10.1002/jcb.21220

119. 119.

     Krieg C, Nowicka M, Guglietta S, et al. High‐dimensional single‐cell analysis predicts response to anti‐PD‐1 immunotherapy. Nat Med. 2018;9:2579.

     Not in our library10.1038/nm.4466

120. 120.

     Schmall A, Al‐tamari HM, Herold S, et al. Macrophage and cancer cell cross‐talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med. 2015;191:437–447.

     Not in our library10.1164/rccm.201406-1137oc

121. 121.

     Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67:9417–9424.

     Not in our library10.1158/0008-5472.can-07-1286

122. 122.

     Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29:1005–1010.

     Not in our library10.1038/nbt.1989

123. 123.

     Pienta KJ, Machiels J‐P, Schrijvers D, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC‐chemokine ligand 2 (CCL2), in metastatic castration‐resistant prostate cancer. Invest New Drugs. 2012;31:760–768.

     Not in our library10.1007/s10637-012-9869-8

124. 124.

     Nywening TM, Wang‐Gillam A, Sanford DE, et al. Targeting tumour‐associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single‐centre, open‐label, dose‐finding, non‐randomised, phase 1b trial. Lancet Oncol. 2016;17:651–662.

     Not in our library10.1016/s1470-2045(16)00078-4

125. 125.

     Bonapace L, Coissieux M‐M, Wyckoff J, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515:130–133.

     Not in our library10.1038/nature13862

126. 126.

     Yu YRA, Fong AM, Combadiere C, Gao JL, Murphy PM, Patel DD. Defective antitumor responses in CX3CR1‐deficient mice. Int J Cancer. 2007;121:316–322.

     Not in our library10.1002/ijc.22660

127. 127.

     Hyakudomi M, Matsubara T, Hyakudomi R, et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 2008;15:1775–1782.

     Not in our library10.1245/s10434-008-9876-3

128. 128.

     Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol. 2012;106:386–392.

     Not in our library10.1002/jso.23095

129. 129.

     Jung K, Heishi T, Incio J, et al. Targeting CXCR4‐dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer. Proc Natl Acad Sci USA. 2017;114:10455–10460.

     Not in our library10.1073/pnas.1710754114

130. 130.

     Welford AF, Biziato D, Coffelt SB, et al. TIE2‐expressing macrophages limit the therapeutic efficacy of the vascular‐disrupting agent combretastatin A4 phosphate in mice. J Clin Invest. 2011;121:1969–1973.

     Not in our library10.1172/jci44562

131. 131.

     Van Overmeire E, Stijlemans B, Heymann F, et al. M‐CSF and GM‐CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 2016;76:35–42.

     Not in our library10.1158/0008-5472.can-15-0869

132. 132.
     Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy · 2017

     No notice
133. 133.

     Aharinejad S, Paulus P, Sioud M, et al. Colony‐stimulating factor‐1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004;64:5378–5384.

     Not in our library10.1158/0008-5472.can-04-0961

134. 134.

     DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67.

     Not in our library10.1158/2159-8274.cd-10-0028

135. 135.

     Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF‐1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;2018:1264–1272.

     Not in our library10.1038/nm.3337

136. 136.

     Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor‐associated macrophages with Anti‐CSF‐1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846–859.

     Not in our library10.1016/j.ccr.2014.05.016

137. 137.

     Neubert NJ, Schmittnaegel M, Bordry N, et al. T cell‐induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10.

     Not in our library10.1126/scitranslmed.aan3311

138. 138.

     Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor‐infiltrating macrophages and improves response to T‐cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057–5069.

     Not in our library10.1158/0008-5472.can-13-3723

139. 139.

     Beffinger M, de Lara PT, Tugues S, et al. CSF1R‐dependent myeloid cells are required for NK‐mediated control of metastasis. JCI Insight. 2018;3:97792.

     Not in our library10.1172/jci.insight.97792

140. 140.

     Quail DF, Bowman RL, Akkari L, et al. The tumor microenvironment underlies acquired resistance to CSF‐1R inhibition in gliomas. Science. 2016;352:aad3018.

     Not in our library10.1126/science.aad3018

141. 141.

     Kumar V, Donthireddy L, Marvel D, et al. Cancer‐Associated fibroblasts neutralize the anti‐tumor effect of CSF1 receptor blockade by inducing PMN‐MDSC infiltration of tumors. Cancer Cell. 2017;32:654–668.

     Not in our library10.1016/j.ccell.2017.10.005

142. 142.

     June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.

     Not in our library10.1056/nejmra1706169

143. 143.

     Green DS, Nunes AT, David‐Ocampo V, et al. A phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron ® (peginterferon alfa‐2b) and Actimmune ® (interferon gamma‐1b) for intra‐peritoneal administration in recurrent ovarian cancer. J. Transl. Med. 2018;16:196.

     Not in our library10.1186/s12967-018-1569-5

144. 144.

     Norelli M, Camisa B, Barbiera G, et al. Monocyte‐derived IL‐1 and IL‐6 are differentially required for cytokine‐release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;118:1.

     Not in our library10.1038/s41591-018-0036-4

145. 145.

     Long AH, Highfill SL, Cui Y, et al. Reduction of MDSCs with all‐trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 2016;4:869–880.

     Not in our library10.1158/2326-6066.cir-15-0230

146. 146.

     Dietrich J, Baryawno N, Nayyar N, et al. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018;128:281–293.

     Not in our library10.1172/jci90647

Cited by papers we hold 8

• Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials · 2023
  No notice
• Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities · 2021
  No notice
• Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting · 2021
  No notice
• Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review · 2021
  No notice
• Tumor-Associated Macrophages: Recent Insights and Therapies · 2020
  No notice
• Trial watch: dendritic cell vaccination for cancer immunotherapy · 2019
  Not checked
• Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer · 2019
  No notice
• The Ontogeny of Monocyte Subsets · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.